Moderna

Vaccine developer Moderna may slow COVID trials to add at-risk minorities

The company said it has enrolled 21,411 participants in the study so far. It had 17,000 participants as of last week, with 24% from communities of color.

By REUTERS
05/09/2020
Moderna in talks to supply COVID-19 vaccine to Japan

The talks closely follow similar discussions with the European Union to supply its vaccine candidate mRNA-1273.

A volunteer receives an injection in a human clinical trial for a potential vaccine against the nove
Moderna's COVID-19 vaccine shows similar immune response in old and young

Moderna said the immune responses in those aged between 56 and 70 years, above 70 and those in the age-group of 18 and 55 were similar.

By REUTERS
27/08/2020
Moderna in advanced discussion to double COVID-19 vaccines for Europe

"We are scaling up our manufacturing capacity to address the global health crisis with a vaccine that is widely available once approved for use."

Moderna CMO sells shares as final vaccine trials begin, raising concerns

CEO Stéphane Bancel has also cashed out on shares in recent months.

Large US COVID-19 vaccine trials will exclude pregnant women for now

Drugmakers say they first need to make sure the vaccines are safe and effective more generally.

By REUTERS
31/07/2020
Moderna vaccine protects against COVID-19 in monkey study

It appeared to be an improvement over results of AstraZeneca's COVID-19 vaccine in a similar study.

By REUTERS
29/07/2020
Moderna's COVID-19 vaccine candidate moves into late-stage trial

The federal government is supporting Moderna's vaccine project with nearly a billion dollars and has chosen it as one of the first to enter large-scale human trials.

By REUTERS
27/07/2020
Will a coronavirus vaccine be a ‘cure’ for the pandemic?

The answer to this is more complicated than one might think and centers around the question of the strength and longevity of the immune response.

Moderna shares drop as patent ruling goes against the biotech company

The clinical stage biotechnology company has said its development of a vaccine for COVID-19 will not be affected.

Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use